Gokcan Hale, Kayhan Meral Akdogan, Demir Sibel Ozbudak, Kacar Sabite, Cam Pinar, Kaplan Mustafa, Daylak Rabia, Oztuna Derya, Kuran Sedef Özdal, Ari Derya
Department of Gastroenterology, Ankara Yuksek Ihtisas Research and Training Hospital, Ankara, Turkey.
Department of Physical Medicine and Rehabilitation, SUAM, Ankara Physical Medicine and Rehabilitation Training and Research Hospital, Ankara, Turkey.
Hepatol Forum. 2020 May 21;1(2):48-52. doi: 10.14744/hf.2020.2020.0007. eCollection 2020 May.
Chronic liver disease is a risk factor for osteoporosis, osteopenia and bone fractures. In this study, prevalence and risk factors of osteoporosis and vitamin D deficiency and also their effects on survival were investigated in 218 patients with chronic liver disease.
Prevalence of osteoporosis and vitamin D levels was calculated. Risk factors for osteoporosis (gender, age, body mass index, etiology), serum bilirubin, albumin, 25-hydroxy (OH) vitamin D, parathyroid hormone levels, bone mineral density (BMD) with DEXA, bone formation (osteocalcin) and bone resorption (type 1 collagen) levels, Model for End-Stage Liver Disease (MELD) Na and Child-Pugh (CP) score were recorded. The effects of vitamin D levels and BMD on survival were evaluated.
One hundred forty-seven (67.4%) patients were female (mean age, 50.4±11.7). Patients were Child A by 40.8%, Child B by 47.1%, and Child C by 12.1%. Mean MELD Na score was 8.4±2.8. Data of the BMD were established in 218 patients and 25-OH D levels in 122 patients. Mean serum 25-OH D level was 14.26±9.44 ng/mL. Osteoporosis was identified in 42 (19.3%) and osteopenia in 115 (52.8%) patients, according to BMD. Osteocalcin levels and collagen type 1 levels were high in 25.6% and 12.5% of patients, respectively. No statistically difference was found, including gender (p=0.69), age (p=0.38), etiology (p=0.16), BMI (p=0.32), CP score (p=0.42), MELD (0.14), albumin (p=0.11), total bilirubin (p=0.99), Ca (0.67), PTH (0.88), osteocalcin (0.92), collagen type 1(p=0.25) between osteoporotic and non-osteoporotic patients. Patients were followed-up for a median of 30.07±11.83 months after BMD measurement. Fifty-four (24.8%) patients died during the follow-up period, none of them are related to bone fracture. There was no statistically difference on survival between osteoporosis group (32.2±2.3 months) and non-osteoporosis group (37.2±1.7 months; p=0.26) or when patients with 25-OH D ≤10 ng/mL were compared to patients with 25-OH D >20 ng/mL (34.4±2.0 months vs. 39.1±1.6 months, p=0.308).
In conclusion, the prevalence of bone disease was found to be higher in cirrhotic patients. Although osteoporosis and vitamin D deficiency were found to decrease survival, this effect was not statistically significant. We suggest designing multi-institutional and/or multinational studies with larger and more heterogenous patient groups would enable better testing of this phenomenon.
慢性肝病是骨质疏松、骨质减少和骨折的危险因素。在本研究中,对218例慢性肝病患者的骨质疏松和维生素D缺乏的患病率、危险因素及其对生存的影响进行了调查。
计算骨质疏松患病率和维生素D水平。记录骨质疏松的危险因素(性别、年龄、体重指数、病因)、血清胆红素、白蛋白、25-羟基(OH)维生素D、甲状旁腺激素水平、采用双能X线吸收法(DEXA)测定的骨密度(BMD)、骨形成(骨钙素)和骨吸收(1型胶原)水平、终末期肝病模型(MELD)钠评分和Child-Pugh(CP)评分。评估维生素D水平和骨密度对生存的影响。
147例(67.4%)患者为女性(平均年龄50.4±11.7岁)。Child A级患者占40.8%,Child B级患者占47.1%,Child C级患者占12.1%。平均MELD钠评分为8.4±2.8。218例患者建立了骨密度数据,122例患者测定了25-OH D水平。血清25-OH D平均水平为14.26±9.44 ng/mL。根据骨密度,42例(19.3%)患者诊断为骨质疏松,115例(52.8%)患者诊断为骨质减少。25.6%的患者骨钙素水平升高,12.5%的患者1型胶原水平升高。骨质疏松患者与非骨质疏松患者在性别(p=0.69)、年龄(p=0.38)、病因(p=0.16)、体重指数(p=0.32)、CP评分(p=0.42)、MELD(0.14)、白蛋白(p=0.11)、总胆红素(p=0.99)、钙(0.67)、甲状旁腺激素(0.88)、骨钙素(0.92)、1型胶原(p=0.25)方面无统计学差异。在测定骨密度后,患者的中位随访时间为30.07±11.83个月。54例(24.8%)患者在随访期间死亡,均与骨折无关。骨质疏松组(32.2±2.3个月)与非骨质疏松组(37.2±1.7个月;p=0.26)之间或25-OH D≤10 ng/mL的患者与25-OH D>20 ng/mL的患者之间(34.4±2.0个月对39.1±1.6个月,p=0.308)在生存方面无统计学差异。
总之,肝硬化患者的骨病患病率较高。虽然骨质疏松和维生素D缺乏会降低生存率,但这种影响无统计学意义。我们建议设计多机构和/或多国研究,纳入更大且更具异质性的患者群体,以便更好地验证这一现象。